Cutaneous T-Cell Lymphoma  Pipeline Review, H2 2012

Cutaneous T-Cell Lymphoma Pipeline Review, H2 2012

Oct 2012 Global Markets Direct Lymphoma151 Pages Price :
$ 2000

Cutaneous T-Cell Lymphoma Pipeline Review, H2 2012


Global Markets Directs, 'Cutaneous T-Cell Lymphoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma.
  • A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Cutaneous T-Cell Lymphoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Cutaneous T-Cell Lymphoma 12
Cutaneous T-Cell Lymphoma Therapeutics under Development by Companies 14
Cutaneous T-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Pre-Clinical Stage Products 22
Comparative Analysis 22
Cutaneous T-Cell Lymphoma Therapeutics Products under Development by Companies 23
Cutaneous T-Cell Lymphoma Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Cutaneous T-Cell Lymphoma Therapeutics Development 26
Johnson & Johnson 26
Kyowa Hakko Kirin Co., Ltd. 27
Shionogi & Co., Ltd. 28
Seattle Genetics, Inc. 29
Emergent BioSolutions Inc. 30
Novartis AG 31
Eisai Co., Ltd. 32
Allos Therapeutics, Inc 33
Mundipharma International Limited 34
Innate Pharma SA 35
Yaupon Therapeutics, Inc. 36
Cutaneous T-Cell Lymphoma Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
brentuximab vedotin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
panobinostat - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
mogamulizumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
forodesine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
mechlorethamine hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
denileukin diftitox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pralatrexate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
IPH-4101 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
zanolimumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
tazarotene - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Gemcitabine + Pemetrexed Disodium - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
agatolimod sodium - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Doxil + Targretin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
C-CHOP - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
romidepsin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
LBH589 + RAD001 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Therapeutic allogeneic lymphocytes program - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
quisinostat - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
nelarabine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
Carmustine + O6-Benzylguanine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
RAD001 + Revlimid - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
alemtuzumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
vorinostat - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
lenalidomide - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
siplizumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 88
RAD001 + CHOP - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 90
Vorinostat + Beam Therapy - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SMILE - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile 94
Product Description 94
Mechanism of Action 95
R&D Progress 95
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 101
Product Description 101
Mechanism of Action 102
R&D Progress 103
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 105
alefacept - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
lenalidomide - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Gemcitabine + Bexarotene + Fenofibrate - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
DNA-IL-12 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Zolinza + Velcade - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Pralatrexate + Bexarotene - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Bexarotene + Radiation Therapy - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
SHP-141 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Genetically Modified T Cells 1138 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
interferon gamma-1a - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Cutaneous T-Cell Lymphoma Therapeutics Drug Profile Updates 122
Cutaneous T-Cell Lymphoma Therapeutics Discontinued Products 140
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 141
Cutaneous T-Cell Lymphoma Product Development Milestones 144
Featured News & Press Releases 144
Jul 09, 2012: OncoSec Initiates Phase II Clinical Program In Cutaneous T-Cell Lymphoma And Doses First Patient 144
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 144
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 145
May 10, 2012: Seattle Genetics Presents Interim Results From Phase II Trial Of ADCETRIS At Society For Investigative Dermatology Annual Meeting 145
Jan 26, 2012: Seattle Genetics Announces Data From ADCETRIS In Cutaneous T-Cell Lymphoma And Peripheral T-Cell Lymphoma 146
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 147
Jan 18, 2012: Ceptaris Receives Orphan Drug Designation From EMA For Mechlorethamine Gel 148
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride 148
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride 149
Sep 12, 2011: Taiho Pharmaceutical To Launch ZOLINZA Capsules 100mg 149

Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Table


Number of Products Under Development for Cutaneous T-Cell Lymphoma, H2 2012 12
Products under Development for Cutaneous T-Cell Lymphoma Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Johnson & Johnson, H2 2012 26
Kyowa Hakko Kirin Co., Ltd., H2 2012 27
Shionogi & Co., Ltd., H2 2012 28
Seattle Genetics, Inc., H2 2012 29
Emergent BioSolutions Inc., H2 2012 30
Novartis AG, H2 2012 31
Eisai Co., Ltd., H2 2012 32
Allos Therapeutics, Inc, H2 2012 33
Mundipharma International Limited, H2 2012 34
Innate Pharma SA, H2 2012 35
Yaupon Therapeutics, Inc., H2 2012 36
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 43
Cutaneous T-Cell Lymphoma Therapeutics Drug Profile Updates 122
Cutaneous T-Cell Lymphoma Therapeutics Discontinued Products 140
Cutaneous T-Cell Lymphoma Therapeutics Dormant Products 141
Cutaneous T-Cell Lymphoma Therapeutics Dormant Products (Contd..1) 142
Cutaneous T-Cell Lymphoma Therapeutics Dormant Products (Contd..2) 143

List of Chart


Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2012 12
Products under Development for Cutaneous T-Cell Lymphoma Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Route of Administration, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Molecule Type, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 42

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top